参考文献/References:
[1] Collaborators GCRD.Prevalence and attributable health burden of chronic respiratory diseases,1990-2017:A systematic analysis for the global burden of disease study 2017[J].The Lancet Respiratory Medicine,2020,8(6):585-596.
[2] Barnes PJ.Inflammatory endotypes in COPD[J].Allergy,2019,74(7):1249-1256.
[3] Bafadhel M,Pavord ID,Russell REK.Eosinophils in COPD:Just another biomarker?[J].The Lancet Respiratory Medicine,2017,5(9):747-759.
[4] Willebrand R,Voehringer D.Regulation of eosinophil development and survival[J].Current Opinion in Hematology,2017,24(1):9-15.
[5] Wynn TA.Type 2 cytokines:Mechanisms and therapeutic strategies[J].Nature Reviews Immunology,2015,15(5):271-282.
[6] Ikutani M,Yanagibashi T,Ogasawara M,et al.Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity [J].Journal of Immunology,2012,188(2):703-713.
[7] Chan BCL,Lam CWK,Tam LS,et al.IL33:Roles in allergic inflammation and therapeutic perspectives[J].Frontiers in Immunology,2019,10:364.
[8] Schmitz J,Owyang A,Oldham E,et al.IL-33,an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines[J].Immunity,2005,23(5):479-490.
[9] Suzukawa M,Koketsu R,Iikura M,et al.Interleukin-33 enhances adhesion,CD11b expression and survival in human eosinophils[J].Journal of Technical Methods and Pathology,2008,88(11):1245-1253.
[10] Barnes PJ.Inflammatory mechanisms in patients with chronic obstructive pulmonary disease[J].The Journal of Allergy and Clinical Immunology,2016,138(1):16-27.
[11] Mallia P,Message SD,Gielen V,et al.Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation[J].Am J Respir Crit Care Med,2011,183(6):734-742.
[12] Papi A,Bellettato CM,Braccioni F,et al.Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations[J].Am J Respir Crit Care Med,2006,173(10):1114-1121.
[13] Pavord ID,Chanez P,Criner GJ,et al.Mepolizumab for eosinophilic chronic obstructive pulmonary disease[J].The New England Journal of Medicine,2017,377(17):1613-1629.
[14] Criner GJ,Celli BR,Brightling CE,et al.Benralizumab for the prevention of COPD exacerbations[J].The New England Journal of Medicine,2019,381(11):1023-1034.
[15] Criner GJ,Celli BR,Singh D,et al.Predicting response to benralizumab in chronic obstructive pulmonary disease:Analyses of GALATHEA and TERRANOVA studies [J].The Lancet Respiratory Medicine,2020,8(2):158-170.
[16] 刘志为.糖皮质激素治疗外周血嗜酸粒细胞增多的慢性阻塞性肺疾病急性加重期患者的临床疗效[J].实用心脑肺血管病杂志,2017,25(10):95-97.
[17] 王珊珊,谭光波.补肺汤对慢性阻塞性肺疾病肺气肿大鼠血清IFN-γ、IL-4表达水平影响研究[J].陕西中医,2019,40(11):1491-1494.
[18] 张莹莹,李娜苗,范亚莉,等.外周血嗜酸性粒细胞水平对AECOPD患者预后的评估价值[J].陕西医学杂志,2018,47(5):561-563.
[19] Casanova C,Celli BR,Torres JP,et al.Prevalence of persistent blood eosinophilia:Relation to outcomes in patients with COPD [J].The European Respiratory Journal,2017,50(5):1701162.
[20] Yun JH,Lamb A,Chase R,et al.Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease[J].The Journal of Allergy and Clinical Immunology,2018,141(6):2037-2047.
[21] Vedel-Krogh S,Nielsen SF,Lange P,et al.Blood eosinophils and exacerbations in chronic obstructive pulmonary disease:The copenhagen general population study[J].Am J Respir Crit Care Med,2016,193(9):965-974.
[22] Bafadhel M,Peterson S,Blas MA,et al.Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease:A post-hoc analysis of three randomised trials[J].The Lancet Respiratory Medicine,2018,6(2):117-126.
[23] Pascoe S,Barnes N,Brusselle G,et al.Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease:Analysis of the IMPACT trial[J].The Lancet Respiratory Medicine,2019,7(9):745-756.
[24] Singh D,Agusti A,Anzueto A,et al.Global Strategy for the diagnosis,management,and prevention of chronic obstructive lung disease:The GOLD science committee report 2019[J].The European Respiratory Journal,2019,53(5):1900164.
[25] Barnes NC,Sharma R,Lettis S,et al.Blood eosinophils as a marker of response to inhaled corticosteroids in COPD[J].The European Respiratory Journal,2016,47(5):1374-1382.
[26] Mathioudakis AG,Bikov A,Foden P,et al.Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD[J].The European Respiratory Journal,2020,55(5):1902119.
[27] Sivapalan P,Lapperre TS,Janner J,et al.Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation(CORTICO-COP):A multicentre,randomised,controlled,open-label,non-inferiority trial [J].The Lancet Respiratory Medicine,2019,7(8):699-709.
[28] 陈辅萍.慢性阻塞性肺疾病并发感染性肺炎危险因素分析[J].陕西医学杂志,2020,49(1):102-104.
[29] Martinez-Garcia MA,Faner R,Oscullo G,et al.Inhaled steroids,circulating eosinophils,chronic airway infection,and pneumonia risk in chronic obstructive pulmonary disease:A network analysis [J].Am J Respir Crit Care Med,2020,201(9):1078-1085.
[30] Pavord ID,Lettis S,Anzueto A,et al.Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease:a patient-level meta-analysis[J].The Lancet Respiratory Medicine,2016,4(9):731-741.
[31] Kolsum U,Donaldson GC,Singh R,et al.Blood and sputum eosinophils in COPD:Relationship with bacterial load[J].Respiratory Research,2017,18(1):88.
[32] Vedel-Krogh S,Nordestgaard BG,Lange P,et al.Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD[J].The European Respiratory Journal,2018,51(5):1800120.
[33] Hartl S,Breyer MK,Burghuber OC,et al.Blood eosinophil count in the general population:typical values and potential confounders[J].The European Respiratory Journal,2020,55(5):1901874.
[34] Schumann DM,Tamm M,Kostikas K,et al.Stability of the blood eosinophilic phenotype in stable and exacerbated COPD[J].Chest,2019,156(3):456-465.
[35] Landis SH,Suruki R,Hilton E,et al.Stability of blood eosinophil count in patients with COPD in the UK clinical practice research datalink[J].Copd,2017,14(4):382-388.
相似文献/References:
[1]肇 阳,卜 伟,温有锋△.矽肺与人体体成分关系临床研究*[J].陕西医学杂志,2020,49(4):415.
ZHAO Yang,BU Wei,WEN Youfeng..Clinical research on relationship between silicosis and human body composition[J].,2020,49(8):415.
[2]陈 芳,杜锦辉△.机械通气辅以纳洛酮治疗慢性阻塞性肺疾病并呼吸衰竭疗效研究[J].陕西医学杂志,2020,49(4):466.
CHEN Fang,DU Jinhui..Effect of mechanical ventilation combined with naloxone on operation related indexes and therapeutic effect in COPD patients with respiratory failure[J].,2020,49(8):466.
[3]杜锦辉,陈 芳△.BiPAP无创呼吸机治疗慢性阻塞性肺疾病并Ⅱ型呼吸衰竭50例临床研究*[J].陕西医学杂志,2020,49(7):824.[doi:DOI:10.3969/j.issn.10007377.2020.07.015]
DU Jinhui,CHEN Fang..BiPAP non-invasive ventilator in treatment of COPD patients with type Ⅱ respiratory failure:a clinical study of 50 cases[J].,2020,49(8):824.[doi:DOI:10.3969/j.issn.10007377.2020.07.015]
[4]杨文林,倪红燕,王海峰.经鼻高流量氧疗序贯治疗慢性阻塞性肺疾病合并呼吸衰竭临床研究*[J].陕西医学杂志,2020,49(10):1280.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.021]
[5]段 珊,彭 旷△,王卫忠,等.慢性阻塞性肺疾病急性加重期患者血清补体C5a水平及其与肺功能、IL-6、CRP水平相关性研究*[J].陕西医学杂志,2020,49(11):1444.[doi:DOI:10.3969/j.issn.1000-7377.2020.11.019]
DUAN Shan,PENG Kuang,WANG Weizhong,et al.The levels of serum C5a and its association with pulmonary function,IL-6 and CRP levels in patients with acute exacerbation of chronic obstructive pulmonary disease[J].,2020,49(8):1444.[doi:DOI:10.3969/j.issn.1000-7377.2020.11.019]
[6]马俊彦,魏永梅,王登本,等.茚达特罗/格隆溴铵和长效β2受体激动剂/长效M受体阻滞剂治疗慢性阻塞性肺疾病稳定期有效性及不良反应发生Meta分析[J].陕西医学杂志,2021,50(10):1309.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.034]
[7]康 睿,张亚琼.阿比多尔对慢性阻塞性肺疾病大鼠气道炎症及气道黏液高分泌影响的实验研究[J].陕西医学杂志,2022,51(4):391.[doi:DOI:10.3969/j.issn.1000-7377.2022.04.002]
KANG Rui,ZHANG Yaqiong.Effect of abidol on airway inflammation and airway mucus hypersecretion in rats with chronic obstructive pulmonary disease[J].,2022,51(8):391.[doi:DOI:10.3969/j.issn.1000-7377.2022.04.002]
[8]张惠民,杜旭升,范亚莉,等.重症肺炎120例多重耐药菌感染情况及影响因素分析[J].陕西医学杂志,2022,51(7):835.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.016]
ZHANG Huimin,DU Xusheng,FAN Yali,et al.Situation and influencing factors of multidrug-resistant organism infection in 120 patients with severe pneumonia[J].,2022,51(8):835.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.016]
[9]窦 飞,王国清,宋东虎,等.CT评估慢性阻塞性肺疾病肺功能临床研究进展[J].陕西医学杂志,2023,52(7):942.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.038]
DOU Fei,WANG Guoqing,SONG Donghu,et al.Clinical research progress in CT evaluation of pulmonary function in chronic obstructive pulmonary disease[J].,2023,52(8):942.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.038]